JP2009065969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009065969A5 JP2009065969A5 JP2008211027A JP2008211027A JP2009065969A5 JP 2009065969 A5 JP2009065969 A5 JP 2009065969A5 JP 2008211027 A JP2008211027 A JP 2008211027A JP 2008211027 A JP2008211027 A JP 2008211027A JP 2009065969 A5 JP2009065969 A5 JP 2009065969A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- seq
- nos
- complementary
- bases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000023 polynucleotide Polymers 0.000 claims description 426
- 239000002157 polynucleotide Substances 0.000 claims description 426
- 206010017758 Gastric cancer Diseases 0.000 claims description 224
- 201000011549 stomach cancer Diseases 0.000 claims description 224
- 238000007912 intraperitoneal administration Methods 0.000 claims description 206
- 206010027476 Metastasis Diseases 0.000 claims description 200
- 230000000295 complement Effects 0.000 claims description 164
- 230000014509 gene expression Effects 0.000 claims description 141
- 229920001850 Nucleic acid sequence Polymers 0.000 claims description 107
- 239000000203 mixture Substances 0.000 claims description 94
- 108020004707 nucleic acids Proteins 0.000 claims description 92
- 150000007523 nucleic acids Chemical class 0.000 claims description 92
- 239000000523 sample Substances 0.000 claims description 65
- 238000000018 DNA microarray Methods 0.000 claims description 49
- 210000001519 tissues Anatomy 0.000 claims description 20
- 239000012472 biological sample Substances 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 12
- 210000000683 Abdominal Cavity Anatomy 0.000 claims description 6
- 238000010998 test method Methods 0.000 claims description 4
- 210000004027 cells Anatomy 0.000 description 143
- 229920002676 Complementary DNA Polymers 0.000 description 85
- 239000002299 complementary DNA Substances 0.000 description 84
- 239000000047 product Substances 0.000 description 67
- 239000012530 fluid Substances 0.000 description 65
- 230000035897 transcription Effects 0.000 description 63
- 239000003550 marker Substances 0.000 description 61
- 229920001184 polypeptide Polymers 0.000 description 59
- 102000004965 antibodies Human genes 0.000 description 58
- 108090001123 antibodies Proteins 0.000 description 58
- 230000001965 increased Effects 0.000 description 37
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 34
- 238000001356 surgical procedure Methods 0.000 description 33
- -1 aromatic amino acids Chemical class 0.000 description 26
- 238000005406 washing Methods 0.000 description 25
- 238000001514 detection method Methods 0.000 description 23
- 238000003745 diagnosis Methods 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- 239000000243 solution Substances 0.000 description 21
- 210000004408 Hybridomas Anatomy 0.000 description 19
- 230000003247 decreasing Effects 0.000 description 19
- 238000009396 hybridization Methods 0.000 description 16
- 239000000758 substrate Substances 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000003018 immunoassay Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 108010045030 monoclonal antibodies Proteins 0.000 description 13
- 102000005614 monoclonal antibodies Human genes 0.000 description 13
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 229940088598 Enzyme Drugs 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 11
- 238000007796 conventional method Methods 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 238000003127 radioimmunoassay Methods 0.000 description 10
- 210000000628 Antibody-Producing Cells Anatomy 0.000 description 9
- 108020004999 Messenger RNA Proteins 0.000 description 9
- 206010035226 Plasma cell myeloma Diseases 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 230000000875 corresponding Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 229920002106 messenger RNA Polymers 0.000 description 9
- 201000000050 myeloid neoplasm Diseases 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 241000796533 Arna Species 0.000 description 8
- 101700024210 HPT1 Proteins 0.000 description 8
- 101710039435 SPAC2C4.12c Proteins 0.000 description 8
- 102100018690 TPT1 Human genes 0.000 description 8
- 101700073473 TPT1 Proteins 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 239000002609 media Substances 0.000 description 8
- 102100015914 ADSS1 Human genes 0.000 description 7
- 101710031553 ADSS1 Proteins 0.000 description 7
- 101710040542 ATP10B Proteins 0.000 description 7
- 102100005367 ATP10B Human genes 0.000 description 7
- 102100007186 CRTC2 Human genes 0.000 description 7
- 101700036509 CRTC2 Proteins 0.000 description 7
- 102100018513 DUSP6 Human genes 0.000 description 7
- 101710032246 DUSP6 Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 102100020195 ESRP1 Human genes 0.000 description 7
- 101700081420 ESRP1 Proteins 0.000 description 7
- 101700080047 FOXM1 Proteins 0.000 description 7
- 102100017920 FOXM1 Human genes 0.000 description 7
- 102100007779 HSD17B3 Human genes 0.000 description 7
- 101710013457 HSD17B3 Proteins 0.000 description 7
- 101700051853 KLF5 Proteins 0.000 description 7
- 102100005665 KLF5 Human genes 0.000 description 7
- 108010093811 Kazal Pancreatic Trypsin Inhibitor Proteins 0.000 description 7
- 102000001626 Kazal Pancreatic Trypsin Inhibitor Human genes 0.000 description 7
- 102100005773 LETM1 Human genes 0.000 description 7
- 108060004351 LETM1 Proteins 0.000 description 7
- 102100012750 MDK Human genes 0.000 description 7
- 101710017904 MDK Proteins 0.000 description 7
- 101700047445 MPP2 Proteins 0.000 description 7
- 101700007720 MYO9A Proteins 0.000 description 7
- 102100003545 MYO9A Human genes 0.000 description 7
- 101700049033 NLRP1 Proteins 0.000 description 7
- 102100017334 NLRP1 Human genes 0.000 description 7
- 102100018318 PSMA2 Human genes 0.000 description 7
- 101700057431 PSMA2 Proteins 0.000 description 7
- 210000003200 Peritoneal Cavity Anatomy 0.000 description 7
- 210000002784 Stomach Anatomy 0.000 description 7
- 102100017605 UNC119 Human genes 0.000 description 7
- 101710040193 UNC119 Proteins 0.000 description 7
- 108060009229 UTP25 Proteins 0.000 description 7
- 102100019928 UTP25 Human genes 0.000 description 7
- 101710017937 ZNF573 Proteins 0.000 description 7
- 102100020021 ZNF573 Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000036961 partial Effects 0.000 description 7
- 108091008117 polyclonal antibodies Proteins 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 102100000616 ABHD12 Human genes 0.000 description 6
- 101710010201 ABHD12 Proteins 0.000 description 6
- 101710043473 ATP5F1B Proteins 0.000 description 6
- 102100020124 ATP5F1B Human genes 0.000 description 6
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 6
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 6
- 102100011839 CEACAM6 Human genes 0.000 description 6
- 101710043949 CEACAM6 Proteins 0.000 description 6
- 102100003949 CEP70 Human genes 0.000 description 6
- 101700073472 CEP70 Proteins 0.000 description 6
- 102100016939 CLDN4 Human genes 0.000 description 6
- 101710018280 CLDN4 Proteins 0.000 description 6
- 101700024340 DDC Proteins 0.000 description 6
- 102100016784 DDC Human genes 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N Hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 101700085508 KCNH2 Proteins 0.000 description 6
- 101710038203 KIF21B Proteins 0.000 description 6
- 102100007843 KIF21B Human genes 0.000 description 6
- 102100013423 KRT8 Human genes 0.000 description 6
- 101710005531 KRT8 Proteins 0.000 description 6
- 102100014011 MAD2L1 Human genes 0.000 description 6
- 101710036146 MAD2L1 Proteins 0.000 description 6
- 102100011575 MSANTD4 Human genes 0.000 description 6
- 101710031834 MSANTD4 Proteins 0.000 description 6
- 102100019052 NAA16 Human genes 0.000 description 6
- 101700059203 NAA16 Proteins 0.000 description 6
- 102100010617 OR10H4 Human genes 0.000 description 6
- 101710032470 OR10H4 Proteins 0.000 description 6
- 102100017317 PTGR1 Human genes 0.000 description 6
- 101700059544 PTGR1 Proteins 0.000 description 6
- 101700080571 RAB1A Proteins 0.000 description 6
- 102100016104 RAB2B Human genes 0.000 description 6
- 101700050768 RAB2B Proteins 0.000 description 6
- 102100019876 RERG Human genes 0.000 description 6
- 101700038058 RERG Proteins 0.000 description 6
- 101700070405 SDC1 Proteins 0.000 description 6
- 102100010587 SDC1 Human genes 0.000 description 6
- 101710033334 SFTPB Proteins 0.000 description 6
- 102100004536 SFTPB Human genes 0.000 description 6
- 102100004578 SUCLA2 Human genes 0.000 description 6
- 101710031100 SUCLA2 Proteins 0.000 description 6
- 101710035582 TBC1D2B Proteins 0.000 description 6
- 102100017470 TBC1D2B Human genes 0.000 description 6
- 102100008880 TFPI Human genes 0.000 description 6
- 101710034269 TFPI Proteins 0.000 description 6
- 102100008904 TFRC Human genes 0.000 description 6
- 101710036041 TFRC Proteins 0.000 description 6
- 101700047519 TYDC2 Proteins 0.000 description 6
- 101700060459 TYDC5 Proteins 0.000 description 6
- 101710031314 TYRDC-1 Proteins 0.000 description 6
- 101710031313 TYRDC-3 Proteins 0.000 description 6
- 101710004640 ZFYVE1 Proteins 0.000 description 6
- 102100013553 ZFYVE1 Human genes 0.000 description 6
- 230000023298 conjugation with cellular fusion Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000005700 syncytium formation by plasma membrane fusion Effects 0.000 description 6
- 102100014476 AKR1B10 Human genes 0.000 description 5
- 108010019099 Aldo-Keto Reductase Family 1 member B10 Proteins 0.000 description 5
- 101700062299 CENPN Proteins 0.000 description 5
- 102100008796 CENPN Human genes 0.000 description 5
- 102100011793 GTF2IRD1 Human genes 0.000 description 5
- 101710009716 GTF2IRD1 Proteins 0.000 description 5
- 229920000126 Latex Polymers 0.000 description 5
- 210000001165 Lymph Nodes Anatomy 0.000 description 5
- 101700077478 PLS1 Proteins 0.000 description 5
- 102100012668 PLS1 Human genes 0.000 description 5
- 102100005286 SLC44A3 Human genes 0.000 description 5
- 108091006916 SLC44A3 Proteins 0.000 description 5
- 102100010109 SLC4A7 Human genes 0.000 description 5
- 108091006244 SLC4A7 Proteins 0.000 description 5
- 101710041000 TATDN1 Proteins 0.000 description 5
- 102100005621 TATDN1 Human genes 0.000 description 5
- 102100004148 UBAC2 Human genes 0.000 description 5
- 101700071761 UBAC2 Proteins 0.000 description 5
- 230000004520 agglutination Effects 0.000 description 5
- 230000024126 agglutination involved in conjugation with cellular fusion Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000004816 latex Substances 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000002194 synthesizing Effects 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 101710010004 HRNR Proteins 0.000 description 4
- 102100003887 LRIF1 Human genes 0.000 description 4
- 108060004464 LRIF1 Proteins 0.000 description 4
- 101710039102 MAP3K5 Proteins 0.000 description 4
- 102100003436 MAP3K5 Human genes 0.000 description 4
- 206010061289 Metastatic neoplasm Diseases 0.000 description 4
- 108060008522 NOA1 Proteins 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 229920000272 Oligonucleotide Polymers 0.000 description 4
- 108060007039 RIF1 Proteins 0.000 description 4
- 239000007759 RPMI Media 1640 Substances 0.000 description 4
- 101710023373 S100A16 Proteins 0.000 description 4
- 102100010063 S100A16 Human genes 0.000 description 4
- 108020004682 Single-Stranded DNA Proteins 0.000 description 4
- 210000000952 Spleen Anatomy 0.000 description 4
- 230000036462 Unbound Effects 0.000 description 4
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000001394 metastastic Effects 0.000 description 4
- 229960000060 monoclonal antibodies Drugs 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 239000006152 selective media Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 3
- 210000004185 Liver Anatomy 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000890 antigenic Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000002068 genetic Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000003100 immobilizing Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- 102100010115 AKR1B1 Human genes 0.000 description 2
- 101710029068 AKR1B1 Proteins 0.000 description 2
- 101710038073 ALDH11A3 Proteins 0.000 description 2
- 102100002858 ATP5IF1 Human genes 0.000 description 2
- 101710032546 ATP5IF1 Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 229960003896 Aminopterin Drugs 0.000 description 2
- 108010047814 Antigen-Antibody Complex Proteins 0.000 description 2
- 101700007873 BON1 Proteins 0.000 description 2
- 101710010924 CPN1 Proteins 0.000 description 2
- 101700013411 CPNE1 Proteins 0.000 description 2
- 102100014729 CPNE1 Human genes 0.000 description 2
- 101710023456 CYP11B1 Proteins 0.000 description 2
- 229920001405 Coding region Polymers 0.000 description 2
- 238000009007 Diagnostic Kit Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 210000003238 Esophagus Anatomy 0.000 description 2
- 101700025206 GPN1 Proteins 0.000 description 2
- 102100008884 GPN1 Human genes 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229920002459 Intron Polymers 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 101700075357 MYC Proteins 0.000 description 2
- 206010063916 Metastatic gastric cancer Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229940072417 Peroxidase Drugs 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108090000437 Peroxidases Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101710023253 S100A1 Proteins 0.000 description 2
- 102100011028 S100A1 Human genes 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229940104230 Thymidine Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006143 cell culture media Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000029578 entry into host Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000003260 fluorescence intensity Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 125000003372 histidine group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 101700034118 myca Proteins 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010517 secondary reaction Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- HAXFWIACAGNFHA-UHFFFAOYSA-N 2,2'-Dipyridyldisulfide Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020003076 Amidases Proteins 0.000 description 1
- 102000005922 Amidases Human genes 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 240000008371 Bacillus subtilis Species 0.000 description 1
- 229940075615 Bacillus subtilis Drugs 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 229940105657 CATALASE Drugs 0.000 description 1
- 102100003506 CLCN1 Human genes 0.000 description 1
- 101700030266 CLCN1 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N Chloramine-T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229940104302 Cytosine Drugs 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N Cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 208000000718 Duodenal Ulcer Diseases 0.000 description 1
- 210000001198 Duodenum Anatomy 0.000 description 1
- 108010015776 EC 1.1.3.4 Proteins 0.000 description 1
- 102000016938 EC 1.11.1.6 Human genes 0.000 description 1
- 108010053835 EC 1.11.1.6 Proteins 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- 102100011343 GLB1 Human genes 0.000 description 1
- 229940116332 GLUCOSE OXIDASE Drugs 0.000 description 1
- 210000004051 Gastric Juice Anatomy 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017860 Gastritis atrophic Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 206010019375 Helicobacter infection Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- ZCYVEMRRCGMTRW-RNFDNDRNSA-N I-131 Chemical compound [131I] ZCYVEMRRCGMTRW-RNFDNDRNSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940044173 Iodine-125 Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N Irinotecan hydrochloride Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 102100012253 KRT20 Human genes 0.000 description 1
- 101710026195 KRT20 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenases Human genes 0.000 description 1
- 108091000084 L-lactate dehydrogenases Proteins 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108060001084 Luciferase family Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 210000002751 Lymph Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 210000001809 Melena Anatomy 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 108060005549 NPR3 Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 101700033269 PHOT1 Proteins 0.000 description 1
- 101710018056 PSMC2 Proteins 0.000 description 1
- 229960001592 Paclitaxel Drugs 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- LLKYUHGUYSLMPA-UHFFFAOYSA-N Phosphoramidite Chemical compound NP([O-])[O-] LLKYUHGUYSLMPA-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229920001914 Ribonucleotide Polymers 0.000 description 1
- 102000037180 SLC4A3 Human genes 0.000 description 1
- 108091006239 SLC4A3 Proteins 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 description 1
- 229920000972 Sense strand Polymers 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229940063683 Taxotere Drugs 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine Kinase Proteins 0.000 description 1
- 229940113082 Thymine Drugs 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 210000003462 Veins Anatomy 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- XJMADGVNUAOHNT-UHFFFAOYSA-N [N-]=C=S.ClC1=CC(=NN=N1)Cl Chemical class [N-]=C=S.ClC1=CC(=NN=N1)Cl XJMADGVNUAOHNT-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 101700086548 ale1 Proteins 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000000692 anti-sense Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 101700071850 clc1 Proteins 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 1
- 230000003899 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 238000009217 hyperthermia therapy Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000011591 microinvasive gastric cancer Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000683 nonmetastatic Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical class O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000001402 polyadenylating Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002102 polyvinyl toluene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000644 propagated Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000002683 reaction inhibitor Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229920002973 ribosomal RNA Polymers 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000000391 smoking Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229930003347 taxol Natural products 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2008211027A JP2009065969A (ja) | 2007-08-21 | 2008-08-19 | 胃ガン腹腔内転移判定用組成物及び方法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007215117 | 2007-08-21 | ||
| JP2008211027A JP2009065969A (ja) | 2007-08-21 | 2008-08-19 | 胃ガン腹腔内転移判定用組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009065969A JP2009065969A (ja) | 2009-04-02 |
| JP2009065969A5 true JP2009065969A5 (fr) | 2012-11-29 |
Family
ID=40602888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008211027A Pending JP2009065969A (ja) | 2007-08-21 | 2008-08-19 | 胃ガン腹腔内転移判定用組成物及び方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2009065969A (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2834430A1 (fr) * | 2011-04-25 | 2012-11-01 | Toray Industries, Inc. | Composition pour la prediction de la sensibilite a une therapie par trastuzumab chez des patients atteints d'un cancer du sein, et procede l'utilisant |
-
2008
- 2008-08-19 JP JP2008211027A patent/JP2009065969A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5524276B2 (ja) | 食道ガンを検出するための組成物及び方法 | |
| JP5435529B2 (ja) | 腎ガン診断、腎ガン患者予後予測のための組成物および方法 | |
| US8945849B2 (en) | Method for diagnosing esophageal cancer | |
| KR101032607B1 (ko) | 간암 진단용 단백질성 마커 | |
| US7910316B2 (en) | Kit and method for detecting urothelial cancer | |
| CN106434870A (zh) | ncRNA及其用途 | |
| CN103233063A (zh) | 前列腺癌标志物spink1及其应用 | |
| WO2006105642A1 (fr) | Marqueurs biologiques pour la detection du cancer du poumon et utilisations de ceux-ci | |
| US20100304410A1 (en) | Method of assessing colorectal cancer status in an individual | |
| CN112345755A (zh) | 乳腺癌的生物标志物及其应用 | |
| CN107255711A (zh) | 骨桥蛋白用于制备或筛选慢加急性肝衰竭诊断试剂的用途 | |
| JP2009065969A5 (fr) | ||
| JP2009065969A (ja) | 胃ガン腹腔内転移判定用組成物及び方法 | |
| JP2009168686A (ja) | 大腸癌の診断又は検出のための組成物及び方法 | |
| JP2009092561A (ja) | ジヒドロピリジン受容体抗体レベルに基づく胸腺腫合併重症筋無力症の診断方法 | |
| JP2010000041A (ja) | 食道ガン転移判定用組成物及び方法 | |
| JP2021089220A (ja) | がんを診断するための方法、がん診断用組成物、がん診断用キット、がんの状態を評価する方法、並びにがん予防薬及び／又は治療薬をスクリーニングする方法 | |
| JP2008263840A (ja) | 胃ガンの診断又は検出のための組成物及び方法 | |
| JP2008267963A (ja) | 大腸ガンの診断または検出のための組成物及び方法 |